| 0.3 mg RBZ vs. sham | 0.5 mg RBZ vs. sham | Dex IVT 0.35 mg vs. sham | Dex IVT 0.7 mg vs. sham | Laser vs. no treatment/observation | IVB vs. sham | IVB vs. laser |
---|---|---|---|---|---|---|---|
BRVO | Â | Â | Â | Â | Â | Â | Â |
Mean change in BCVA (measured by ETDRS scale unless otherwise specified), mean difference (95% CI) | 9.30* (6.40, 12.20) [43] | 11.0* (7.83, 14.17) [43] | NR | 2.5* (0.6, 4.3) [18] | Battaglia Parodi et al (9 months), -0.01, (-0.08, +0.06)a[45] | 6 weeks, logMAR; –0.26* (–0.44, –0.08)b[49] | logMAR; –0.11 (–0.01, –0.21)b[50] |
Number of patients gaining ≥ 15 letters, OR (95% CI) | 3.05* (1.84, 5.07) [43] | 3.88* (2.32, 6.49) [43] | NR | 1.19 (0.80, 1.78) [18] | NR | NR | logMAR; 3.14 (0.68, 14.5) [50] |
Number of patients gaining ≥ 10 letters, OR (95% CI) | 4.22* (2.51, 7.09) [43] | 5.48* (3.18, 9.44) [43] | 1.07 (0.70, 1.62) [18] | 1.43* (1.01, 2.01) [18] | BVOS (36 months), [6] 3.16* (1.25, 8.00) | NR | NR |
CRVO | Â | Â | Â | Â | Â | Â | Â |
Mean change in BCVA, mean difference (95% CI) | 11.9* (8.01, 15.79) [42] | CRUISE, 14.10* (10.51, 17.69) [42] ROCC, 11.0* (–2.48, 24.48) [44] | NR | NR, NSc | NR | NR | NR |
Number of patients gaining ≥ 15 letters, OR (95% CI) | 4.22* (2.38, 7.47) [42] | CRUISE, 4.48* (2.52, 7.94) [42] | 1.46 (0.76, 2.79) [18] | 1.54 (0.79, 2.98) [18] | NR | NR | NR |
Number of patients gaining ≥ 10 letters, OR (95% CI) | 4.82* (2.84, 8.18) [42] | CRUISE, 7.12* (4.12, 12.29) [42] | NR | 1.15 (0.67, 1.97) [18] | CVOS (12 months), 1.90 (0.65, 5.54) [10] Laatikainen et al (12 months), 1.00 (0.13, 7.75) [46] May et al (24 months), 0.70 (0.14, 3.56) [47] | NR | NR |
BRVO or CRVO | Â | Â | Â | Â | Â | Â | Â |
Number of patients gaining ≥ 10 letters, OR (95% CI) | NR | NR | NR | 3 months, 9.82* (2.84, 33.99) [20] | NR | NR | NR |